We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Read MoreHide Full Article
Biogen Inc. (BIIB - Free Report) reported $2.65 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 7.3%. EPS of $5.47 for the same period compares to $5.28 a year ago.
The reported revenue represents a surprise of +13.89% over the Zacks Consensus Estimate of $2.32 billion. With the consensus EPS estimate being $3.93, the EPS surprise was +39.19%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Biogen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue- Product- Rare Disease- SKYCLARYS - United States: $78 million compared to the $75.44 million average estimate based on 23 analysts.
Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- Rest of world: $182.4 million versus the 23-analyst average estimate of $171.91 million. The reported number represents a year-over-year change of -14.6%.
Revenue- Product- Rare Disease- SKYCLARYS - Rest of World: $52.3 million versus $53.63 million estimated by 23 analysts on average.
Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- United States: $272.2 million versus $203.91 million estimated by 23 analysts on average. Compared to the year-ago quarter, this number represents a +9.5% change.
Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- Total: $454.6 million versus $372.66 million estimated by 27 analysts on average. Compared to the year-ago quarter, this number represents a -1.6% change.
Revenue- Product- Rare Disease- SPINRAZA- Total: $392.7 million versus $396.92 million estimated by 27 analysts on average. Compared to the year-ago quarter, this number represents a -8.5% change.
Revenue- Product- Rare Disease- SKYCLARYS- Total: $130.3 million versus the 26-analyst average estimate of $128.37 million. The reported number represents a year-over-year change of +30.3%.
Revenue- Product, net: $1.88 billion compared to the $1.72 billion average estimate based on 26 analysts. The reported number represents a change of -1.1% year over year.
Revenue- Anti-CD20 therapeutic programs: $467.3 million compared to the $431.19 million average estimate based on 26 analysts. The reported number represents a change of +5.1% year over year.
Revenue- Product- Multiple Sclerosis (MS)- Fumarate- VUMERITY- Total: $212.3 million versus the 25-analyst average estimate of $170.04 million. The reported number represents a year-over-year change of +28.1%.
Revenue- Product- Multiple Sclerosis (MS)- Fumarate- TECFIDERA- Total: $193.6 million versus $178.41 million estimated by 25 analysts on average. Compared to the year-ago quarter, this number represents a -23.2% change.
Revenue- Product- Other- ZURZUVAE- Total: $46.4 million versus $32.61 million estimated by 24 analysts on average.
Shares of Biogen have returned -4.9% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Biogen Inc. (BIIB - Free Report) reported $2.65 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 7.3%. EPS of $5.47 for the same period compares to $5.28 a year ago.
The reported revenue represents a surprise of +13.89% over the Zacks Consensus Estimate of $2.32 billion. With the consensus EPS estimate being $3.93, the EPS surprise was +39.19%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Biogen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:View all Key Company Metrics for Biogen here>>>
Shares of Biogen have returned -4.9% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.